Abstract: Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%– 10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1β, has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.

Keywords: familial mediterranean fever, Canakinumab, anti-IL1 therapy


中文翻译：

---

卡那基单抗治疗家族性地中海热的功效，安全性和耐受性：文献综述

摘要：家族性地中海热（FMF）是最普遍的遗传性自体炎症。在大多数患者中，秋水仙碱可以预防发烧和发炎。但是，有5％-10％的患者对秋水仙碱治疗有抗药性，而相似比例的患者不能耐受预防发作所需的秋水仙碱剂量。对于这些患者，Canakinumab是一种针对IL-1β的完整人类抗体，最近已被FDA和EMA批准。在本文中，我们对Canakinumab在不能耐受秋水仙碱或对秋水仙碱治疗耐药的FMF患者中的长期疗效，安全性和耐受性进行了系统综述。

关键词：家族性地中海热，卡那基单抗，抗IL1疗法